Granulomatosis With Polyangiitis Treatment Market Report 2026

Granulomatosis With Polyangiitis Treatment Market Overview

• Granulomatosis With Polyangiitis Treatment market size has reached to $2.55 billion in 2025 • Expected to grow to $3.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Rising Prevalence Of Autoimmune Diseases Drives Growth In Market • Market Trend: Advancements In Biologics And Steroid Optimization Improve EGPA Treatment • North America was the largest region in 2025.

What Is Covered Under Granulomatosis With Polyangiitis Treatment Market?

Granulomatosis with Polyangiitis (GPA) treatment involves the use of medications to control inflammation, suppress the immune system, and prevent organ damage. Granulomatosis with polyangiitis (GPA) is a rare autoimmune disorder causing inflammation of small to medium blood vessels, leading to restricted blood flow and tissue damage, particularly in the respiratory tract and kidneys. Treatment primarily involves immunosuppressive therapies, such as corticosteroids and biologics, to reduce inflammation and prevent organ damage. The main drug types of granulomatosis with polyangiitis treatment are steroids, immunosuppressants, and others. Steroids are anti-inflammatory drugs that help reduce swelling and suppress the immune system. In granulomatosis with polyangiitis, they are often used in combination with other medications to manage symptoms. Treatment types involved are immunosuppressants and corticosteroids, and various routes of administration include oral and intravenous. They are distributed through different channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used by multiple end users, such as hospitals, home care, specialty clinics, and others.

What Is The Granulomatosis With Polyangiitis Treatment Market Growth Forecast?

The granulomatosis with polyangiitis treatment market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to biologic drug innovation, precision autoimmune treatment, early diagnostic screening, chronic disease management demand, specialty clinic growth. Major trends in the forecast period include increased use of biologic therapies, rising demand for early autoimmune diagnosis, expansion of long-term disease remission strategies, growth of combination immunosuppressive therapies, improved monitoring of organ damage.

Global Granulomatosis With Polyangiitis Treatment Market Segmentation

1) By Drug Type: Steroids, Immunosuppressants, Other Drug Types 2) By Route Of Administration: Oral, Intravenous 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone 2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab 3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

What Are The Drivers Of The Granulomatosis With Polyangiitis Treatment Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the granulomatosis with polyangiitis treatment market going forward. Autoimmune diseases occur when the body's immune system mistakenly attacks its healthy cells and tissues, leading to inflammation and damage in various organs. The increasing prevalence of autoimmune diseases is due to environmental triggers (such as infections, chemicals, or pollutants) and lifestyle changes. Granulomatosis with polyangiitis treatment is helpful for autoimmune diseases by utilizing immunosuppressive therapies such as corticosteroids and cyclophosphamide, which help control inflammation and prevent organ damage, making early intervention and tailored treatment crucial for managing other autoimmune conditions with similar mechanisms. For instance, in June 2023, according to a report published by the Office for National Statistics, a UK-based government department, the global population of people with multiple sclerosis (MS) (an autoimmune disease) in 2023 was 2.9 million, up from 2.8 million in 2022. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the granulomatosis with polyangiitis treatment industry. The rising healthcare expenditure is expected to propel the growth of the granulomatosis with polyangiitis treatment market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come at higher costs, leading to greater overall spending in healthcare. Rising healthcare expenditure is helping advance granulomatosis with polyangiitis treatment by enabling greater investment in early diagnosis, access to advanced immunosuppressive and biologic therapies, and improved patient management infrastructure. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the rising healthcare expenditure is driving the growth of the granulomatosis with polyangiitis treatment industry.

Key Players In The Global Granulomatosis With Polyangiitis Treatment Market

Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F Hoffmann La Roche Ltd, Sanofi S A, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, ChemoCentryx Inc, Medac Pharma Inc, InflaRx GmbH, AbbVie Inc, Johnson & Johnson, Bristol Myers Squibb Company, Novartis AG, Biogen Inc, Takeda Pharmaceutical Company Limited, UCB S A, Bayer AG, Merck & Co Inc, Eli Lilly and Company, Astellas Pharma Inc

Global Granulomatosis With Polyangiitis Treatment Market Trends and Insights

Major companies operating in the granulomatosis with polyangiitis treatment market are focusing on developing innovative products, such as oral corticosteroids, to offer patients more effective treatment options that improve disease management while minimizing the long-term side effects of steroid use. Oral corticosteroids are a medication that reduces inflammation and suppresses the immune system. They are commonly used to treat allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a UK-based pharmaceutical company, announced Fasenra (bevacizumab) had been approved in the European Union, a Europe-based political and economic union of European countries, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The approval follows positive results from the MANDARA Phase III trial, demonstrating the efficacy of Fasenra in achieving remission and reducing reliance on oral corticosteroids in EGPA patients.

Regional Outlook

North America was the largest region in the granulomatosis with polyangiitis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Granulomatosis With Polyangiitis Treatment Market?

The granulomatosis with polyangiitis treatment market includes sales of symptomatic treatment, monoclonal antibodies, and plasmapheresis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Granulomatosis With Polyangiitis Treatment Market Report 2026?

The granulomatosis with polyangiitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the granulomatosis with polyangiitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.